The long-term effects of respiratory viral infections such as COVID-19 are a major public health burden. Some estimates suggest over 65 million people...
Vous n'êtes pas connecté
Researchers show for the first time that engineered human plasma B cells can be used to treat a disease—specifically leukaemia a humanised animal model. The results mark a key step in the realization of ePCs as therapies to treat cancer, auto-immune disorders, and protein deficiency disorders. The results appear July 2 in the journal Molecular Therapy. [...]
The long-term effects of respiratory viral infections such as COVID-19 are a major public health burden. Some estimates suggest over 65 million people...
The long-term effects of respiratory viral infections such as COVID-19 are a major public health burden. Some estimates suggest over 65 million people...
WashU Medicine researchers have designed, in mice, an approach to minimizing the damage from a spinal cord injury through the use of engineered immune...
WashU Medicine researchers have designed, in mice, an approach to minimizing the damage from a spinal cord injury through the use of engineered immune...
Scientists are on the verge of a cancer breakthrough after working out how the body’s immune system targets cells devastated by the disease. A new...
Researchers have discovered an antibody able to neutralize all known variants of SARS-CoV-2, the virus that causes COVID-19, as well as distantly...
Immune checkpoint inhibitors are cancer-fighting drugs that help the immune system do its job of detecting and attacking tumour cells. Programmed Cell...
The conditions within a person’s home, family and community affect their ability to stay healthy. Scientists studying these social determinants of...
Scientists at the University of Southampton have uncovered how the immune system's natural killer cells can target a protein known as XPO1, which...
Iron Deficiency Anemia Market As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the...